Application progress on the predictive value of immune-related adverse events for ef-ficacy in immunotherapy of extensive stage-small cell lung cancer
10.12354/j.issn.1000-8179.2025.20251037
- VernacularTitle:免疫相关不良事件在广泛期小细胞肺癌免疫治疗中疗效预测价值研究进展
- Author:
Zhang CUICUI
1
;
Chen PENG
1
Author Information
1. 天津医科大学肿瘤医院肺部肿瘤内科,国家恶性肿瘤临床医学研究中心,天津市恶性肿瘤临床医学研究中心,天津市"肿瘤防治"重点实验室(天津市 300060)
- Publication Type:Journal Article
- Keywords:
extensive stage-small cell lung cancer(ES-SCLC);
immune checkpoint inhibitors(ICIs);
immune-related adverse reactions(ir-AEs);
therapeutic efficacy
- From:
Chinese Journal of Clinical Oncology
2025;52(15):801-806
- CountryChina
- Language:Chinese
-
Abstract:
Small cell lung cancer(SCLC)is a neuroendocrine tumor that is highly heterogeneous and invasive.SCLC is prone to distant meta-stasis,and most patients are diagnosed in the extensive stage(ES-SCLC)after metastasis has occurred.Immune checkpoint inhibitors(ICIs)combined with chemotherapy currently serve as standard first-line treatment for ES-SCLC.However,the accompanying immune-related ad-verse events(irAEs)may affect patients'quality of life and treatment efficacy.Studies suggest a correlation between irAE occurrence and treatment response rates as well as survival benefits,although the mechanisms underlying this correlation are not fully understood.This art-icle provides a comprehensive review of the application of ICIs in ES-SCLC,exploring the association between irAEs and clinical ICI efficacy,the potential underlying biological mechanisms of their association,predictive biomarkers of irAEs,and strategies for managing irAEs.This study offers insights for optimizing immunotherapy for treating ES-SCLC.
